In conclusion, this study showed that genetic or pharmacological inhibition of PTGR2 prevented diet-induced obesity, reduced insulin resistance, and decreased hepatic steatosis via increasing endogenous PPARγ ligands without adverse side effects such as fluid retention and osteoporosis. Here, PTGR2 is linked to obesity due to melanocortin 4 receptor deficiency.